Pharma companies focusing more on core areas'
Pharma | Company results | By BioSpectrum Bureau | 0 Comment | 05 May, 2014
Bangalore: On April 25, 2014, Biocon declared its FY14 performance results at its Bangalore campus, revealing 16 percent growth in its revenues, with revenues touching Rs 2,933 crore, follo...Read more
Biogen Idec multiple sclerosis drug gets FDA nod
Pharma | Regulatory | By BioSpectrum Bureau | 0 Comment | 15 Apr, 2013
Singapore: Biogen Idec received approval for Tecfidera (dimethyl fumarate) as a new first-line oral treatment for people with relapsing forms of multiple sclerosis (MS) from the US FDA. Tec...Read more
Sanofi reports +ve results despite patent expirations
Pharma | Company results | By BioSpectrum Bureau | 0 Comment | 11 Feb, 2013
Singapore: Sanofi reported sales of $11.40 billion (€8,526 million), an increase of 0.2 percent, during the fourth quarter (Q4) of 2012. Exchange rate movements had a positive effect ...Read more
Pharma sector witnesses dip in hiring
Pharma | News | By BioSpectrum Bureau | 0 Comment | 13 Nov, 2012
New Delhi: The recruitment levels for the pharma sector in India witnessed a decrease of five percent in October 12, when compared to last month. This negative trend has been continuously h...Read more
Novartis appoints a new oncology president
Pharma | News | By BioSpectrum Bureau | 0 Comment | 02 Jun, 2014
Singapore: Swiss drug giant Novartis, announced on June 1, that it had appointed Mr Bruno Strigini as the president of its oncology division. Mr Stringini had earlier served Merck & Co....Read more
Prana Alzheimer's trial shows +ve results
Pharma | News | By BioSpectrum Bureau | 0 Comment | 08 Apr, 2013
Singapore: Prana Biotechnology reported on the progress of its lead development asset PBT2, which is in phase II trials for Huntington disease and Alzheimer's disease. Across the two trials...Read more
India may halt foreign investment in pharma
Pharma | News | By BioSpectrum Bureau | 0 Comment | 20 Sep, 2013
Singapore: As a resolution to the ongoing debate about whether to restrict foreign direct investment (FDI) in the existing pharmaceutical projects in India, the country's health ministry ha...Read more
Novartis posts 20 percent rise in Q1 profit
Pharma | Company results | By BioSpectrum Bureau | 0 Comment | 29 Apr, 2014
Singapore: Novartis announced that it has recorded a 20 percent rise in its first-quarter profit. Reports said that the net profit attributable to shareholders climbed to $2.94 billion fro...Read more
Study shows Lipitor well-tolerated among Asians
Pharma | News | By BioSpectrum Bureau | 0 Comment | 07 Nov, 2012
Singapore: A large-scale retrospective database analysis on atorvastatin (Lipitor) by Astellas Pharma and Pfizer Japan has demonstrated that atorvastatin is as well tolerated by the Asian p...Read more
Astellas to do interim analysis of cancer trial
Pharma | News | By BioSpectrum Bureau | 0 Comment | 03 Apr, 2013
Singapore: Medivation and Astellas Pharma have established an updated interim analysis plan for the Prevail trial, a global phase III clinical trial evaluating Xtandi (enzalutamide) capsule...Read more
Novartis acquires cancer firm CoStim
Pharma | News | By BioSpectrum Bureau | 0 Comment | 18 Feb, 2014
Singapore: Global pharmaceutical firm, Novartis, has acquired CoStim Pharmaceuticals, a privately held biotechnology company, broadening its cancer immunotherapy research program. Increasi...Read more
AIDS 2014 kicks off in Melbourne
Pharma | News | By BioSpectrum Bureau | 0 Comment | 21 Jul, 2014
Singapore: 20th International AIDS Conference (AIDS 2014), kicked off in Melbourne on July 20th, with a gathering of over 12,000 participants including global leaders, researchers, activist...Read more
EMA: Osteoporosis drug causes heart problems
Pharma | Regulatory | By BioSpectrum Bureau | 0 Comment | 29 Apr, 2013
Singapore: The European Medicine Agency (EMA) recommended restriction in the use of the osteoporosis medicine Protelos/Osseor, following an assessment of data showing an increased risk of s...Read more
FDA re-inspects AMRI Burlington facility
Pharma | Regulatory | By BioSpectrum Bureau | 0 Comment | 24 Jul, 2013
Singapore: FDA has issued warning letter to Albany Molecular Research (AMRI) in connection with an inspection of the company's pharmaceutical manufacturing facility located in Burlington, M...Read more
ShangPharma appoints committee chairman
Pharma | News | By BioSpectrum Bureau | 0 Comment | 18 Jul, 2012
Singapore: ShangPharma, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, has appointed Mr Yuk Lam Lo as the chairman of the independent c...Read more
Pharma industry sets eyes on $25 bn exports by 2014
Pharma | News | By BioSpectrum Bureau | 0 Comment | 02 Oct, 2012
Hyderabad: Innovation and government support are key to reach the $25 billion export target set by the India government for the pharmaceutical sector. Heads of major pharma companies, who g...Read more
Teva and Lonza terminate biosimilars joint venture
Pharma | News | By BioSpectrum Bureau | 0 Comment | 26 Jul, 2013
Singapore: Teva Pharmaceutical Industries and Lonza Group have conducted a strategic review of the Teva-Lonza Joint Venture (TL-JV) and have decided to discontinue their collaboration for ...Read more
GSK admits to fraud in the US, pays $3 bn in penalty
Pharma | Analysis | By BioSpectrum Bureau | 0 Comment | 05 Jul, 2012
Bangalore: British pharmaceutical giant GlaxoSmithKline (GSK), which was facing civil and criminal liabilities in the US for unlawful promotion of certain prescription drugs and failure to ...Read more